Enanta Pharmaceuticals Inc (ENTA)

[willyw]

Thank you. ; )
I have come to rather enjoy your "the flight you booked is going to crash" type posts.
I've no idea why you are fixated on Enanta; I wager you are just trying to be helpful. : )

For those investing there is always that school of thought that one should jump out of the plane before it crashes. I take a slightly different view; stocks go up and down independent of any apparent reason. For instance, money sometimes rotates in or out of a stock and then (for instance when a drug is de-risked), then money might move back in. Many have gone to cash in this period of uncertainty- that is not a referendum on Enanta's covid program per se.

IMHO people are waiting for results of Enanta's covid drug which could arrive in mere weeks.
Any selling hasn't been at concerning volume (once again my opinion).

Pfizer's sales of Paxlovid reached $18.9 billion in 2022.
Pfizer expects that revenue to drop 58% to $8 billion in 2023.
I expect that in mere weeks Enanta's EDP- 235 covid drug will be shown to be more effective than Paxlovid, be once a day dosing and non-boosted- thus making it safe for large groups without worrisome drug interactions.
IF it is your contention that covid is over, then Enanta's drug could be best in class in a niche where further covid drug development is scuttled.
This is very much like the HCV market today, right?

It may also be that the drug could show promise in long covid or prophylaxis, or save more live in high risk groups. If it is more efficacious it could reduce or eliminate rebounds.

I'm content to wait for results. I could be wrong, but I'm not about to jump out of the plane right before it lands based on your analytical skills.

One thing I am reasonably certain of;
If Enanta's results show that it is more efficacious than Paxlovid, is indeed once a day dosing
you will probably still opine that it can't work, and will fail.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170538068

I've been wrong before, and I allow I may be this time too. : )
My view is that if you look at drug effects on heathies that presumably will recover regardless you are almost deliberately trying to avoid looking at groups where results will be more highly differentiated. This is true in Covid and I think may also be shown in RSV.

We will see.